Volume Alert - CLDX 18.11 Celldex Therapeutics Inc
Post# of 98
Posted On: 11/17/2014 11:05:02 AM
Volume Alert - CLDX 18.11 Celldex Therapeutics Inc $CLDX Hit a high today of 18.45 Closing the day 10:30 at 18.11 +3.95 +27.90% With a day low of 16.32 and a total volume of 6,756,383.
CLDX Recent Posts: http://investorshangout.com/Celldex-Therapeut...LDX-53702/
CLDX Celldex Therapeutics Inc Recent Headline News
Celldex Therapeutics (CLDX) Stock Surges Following Brain Tumor Immunotherapy Results
at The Street - 2 mins ago
Shares of Celldex Therapeutics (CLDX) were up in morning trading Monday after the company announced positive results of its immunotherapy in treating a certain type of brain tumor.
CLDX: 17.65 (+3.49)
Celldex Therapeutics: Interim Results For Phase 2 ReACT Trial Are Very Encouraging
Smith On Stocks - at Seeking Alpha - 35 mins ago
CLDX: 17.65 (+3.49)
Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - 1 hr 49 mins ago
CADC: 6.17 (+1.91), INO: 9.98 (-1.02), CLDX: 17.65 (+3.49), HAL: 51.13 (-3.95), ROX: 1.78 (-0.20), SNSS: 1.88 (+0.21), DNR: 9.81 (-1.39), DWA: 22.60 (-3.42), GSAT: 2.79 (-0.18), CMGE: 26.30 (+0.70), FOLD: 6.61 (+0.92), BHI: 67.26 (+7.37)
Celldex up premarket on positive rindopepimut data
Seeking Alpha - at Seeking Alpha - 2 hrs 6 mins ago
CLDX: 17.65 (+3.49)
Biotech Equities Technical Coverage - Orexigen Therapeutics, Novavax, Sunesis Pharma, Celldex Therapeutics, and Navidea Biopharma
PR Newswire - 2 hrs 19 mins ago
Investor-Edge has initiated coverage on the following equities: Orexigen Therapeutics Inc. (NASDAQ: OREX), Novavax Inc. (NASDAQ: NVAX), Sunesis Pharmaceuticals Inc. (NASDAQ: SNSS), Celldex Therapeutics Inc. (NASDAQ: CLDX), and Navidea Biopharmaceuticals Inc. (NYSE MKT: NAVB). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Friday, November 14, 2014, the NASDAQ Composite ended at 4,688.54, up 0.18%, the Dow Jones Industrial Average edged 0.10% lower, to finish the day at 17,634.74, and the S&P 500 closed at 2,039.82, up 0.02%. The gains were broad based as six out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 777.26, down 0.83%, while the index has advanced 9.80% in the last one month. Register for your complimentary reports on these five stocks at:
OREX: 5.57 (-0.08), NAVB: 1.20 (+0.04), NVAX: 5.15 (-0.13), CLDX: 17.65 (+3.49), SNSS: 1.88 (+0.21)
Celldex Therapeutics' (CLDX) CEO Presents Phase 2 ReACT Interim Data at the Society for Neuro-Oncology Annual Meeting (Transcript)
SA Transcripts - at Seeking Alpha - Fri Nov 14, 10:53PM CST
CLDX: 17.65 (+3.49)
After Hour Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Nov 14, 4:38PM CST
HK: 3.04 (-0.06), NTES: 100.29 (-0.35), CIG: 4.87 (+0.05), TSRO: 30.36 (+0.74), DDD: 34.91 (+0.84), CLDX: 17.65 (+3.49), SCMP: 11.83 (+0.53), BVN: 9.23 (+0.02), ABGB: 11.53 (+2.39), SSE: 11.38 (+0.10)
Interim Update from Randomized Phase 2 ReACT Study of Rindopepimut in Recurrent Bevacizumab-naive Glioblastoma Demonstrates Statistically Significant Survival Benefit
GlobeNewswire - Fri Nov 14, 2:35PM CST
-Benefit observed across multiple endpoints in bevacizumab-naïve patients-
CLDX: 17.65 (+3.49)
Celldex Immunotherapy Prolongs Survival for Recurrent Brain Tumor Patients
at The Street - Fri Nov 14, 2:35PM CST
Positive data presented Friday, particularly the statistically significant survival benefit favoring patients treated with rindopepimut, has Celldex planning -- cautiously -- for a conversation with the FDA about accelerated approval.
CLDX: 17.65 (+3.49)
Global Immune Checkpoint Inhibitors Market, 2014-2024: Yervoy, Opdivo and Keytruda to Achieve Blockbuster Status in the Near Future
M2 - Thu Nov 13, 6:55AM CST
Research and Markets (http://www.researchandmarkets.com/research/fkbg4v/immune_checkpoint) has announced the addition of the "Immune Checkpoint Inhibitors Market, 2014 - 2024" report to their offering. The Immune Checkpoint Inhibitors Market, 2014-2024 report provides a comprehensive analysis of the current market landscape and the future outlook of the growing pipeline of Immune Checkpoint Inhibitors. The immuno-oncology market encompasses a myriad of immune checkpoint targeting drugs which can be potentially exploited for the broad range of cancer. CTLA-4 inhibitors were the pioneers in this segment. Yervoy, the flagship molecule from BMS, was the only immunotherapeutic Immune Checkpoint Inhibitor commercially available until other classes recently stepped in. The approval of anti PD-1 drugs and emergence of anti PD-L1 drugs has provided a significant boost to the market. Immune checkpoints are molecules that regulate (stimulate or inactivate) the immune cells. Yervoy (an anti CTLA-4 drug), the foremost drug to be launched in this domain, is currently being mirrored by various other drugs such as Opdivo, Keytruda (both anti PD-1 drugs) and several others under clinical development. The market, with an opportunistic development pipeline, caters to the participation of various market players (big and small) over a common platform. With an ongoing rush to emerge as leaders in the evolving market, various stakeholders have collaborated to establish their foothold in a relatively short time period. Specifically, we expect Yervoy, Opdivo and Keytruda to achieve blockbuster status in the near future. The anticipated success of Immune Checkpoint Inhibitors shall prove to be a harbinger for emerging players and a strong impetus to the development pace of the other pharmaceutical giants. Key Highlights - The market is characterized by the presence of three marketed drugs and 25 drugs in clinical development for oncological indications. This pipeline includes two CTLA-4, eight PD-1 / PD-L1 and 18 novel Immune Checkpoint Inhibitors. The dynamic pipeline also includes several molecules in preclinical / discovery stage; in our research, we identified about 30 such molecules. - BMS, with seven Immune Checkpoint Inhibitors (marketed / clinical development), is the leading player. Other pharmaceutical giants include AstraZeneca, Merck and Roche. Many university spin-offs have emerged in the past two years; their early stage research has been backed by venture funding as well. - Amongst the novel Immune Checkpoint Inhibitors, IDO inhibitors have been the most sought after drug class under development. Though Elotuzumab is the only drug in late stage development, novel checkpoints have paved the way for smaller biotechnology firms to enter the immuno-oncology market. - Collaborations have helped the market reach its current growth trajectory. Specifically, clinical trial collaborations to evaluate Immune Checkpoint Inhibitors as combination therapies are very common; 2014 has already seen 12 such collaborations for a number of molecules. - We expect Immune Checkpoint Inhibitors to be a multi-billion dollar market over the coming decade; during the period 2014 - 2024, our forecast suggests that the market will witness an annualized growth rate of 24.1%. Key Topics Covered: 1. Preface 2. Executive Summary 3. Cancer Therapeutics and Immuno-Oncology 4. Current Market Landscape 5. CTLA-4 Inhibitors: Key Molecules and Future Outlook 6. PD-1 and PD-L1 Inhibitors: Key Molecules and Future Outlook 7. Novel Immune Checkpoint Inhibitors: Key Molecules and Future Outlook 8. Competition in Key Indication Areas 9. Deals and Partnerships 10. Company Profiles 11. Conclusion 12. Appendix 1: Tabulated Data 13. Appendix 2: List of Companies and Organizations Companies Mentioned - Bristol Myer Squibb - AstraZeneca - Merck & Co. - Roche / Genentech - Incyte Corporation - NewLink Genetics - arGEN-X - Seattle Genetics - Pfizer - MacroGenics - Celldex Therapeutics - CureTech - Immutep - Innate Pharma - Sorrento Therapeutics - GlaxoSmithKline - GITR, Inc. For more information visit http://www.researchandmarkets.com/research/fk...checkpoint
MRK: 59.75 (+0.68), INCY: 69.70 (+0.16), CLDX: 17.65 (+3.49), NLNK: 31.48 (+0.94), GSK: 45.87 (+0.13), BMY: 58.19 (+0.24), SRNE: 4.16 (-0.07)
Hematopoietic Stem Cell Transplantation Therapeutic Market Pipeline Overview, Key Players & Drugs Profiles H2 2014
PRWeb - Wed Nov 12, 10:30PM CST
The report "Hematopoietic Stem Cell Transplantation - Pipeline Review, H2 2014" provides comprehensive information on the therapeutic development for Hematopoietic Stem Cell Transplantation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hematopoietic Stem Cell Transplantation and special features on late-stage and discontinued projects. Complete Report is Available @ http://www.rnrmarketresearch.com/hematopoieti...eport.html .
ATNM: 6.00 (+0.08), CLDX: 17.65 (+3.49), ATHX: 1.36 (-0.01), NVS: 94.36 (+0.41)
Critical Alerts For Achillion Pharmaceuticals, Celldex Therapeutics, Kandi Technologies, Illumina and Advanced Micro Devices Released By InvestorsObserver
PR Newswire - Tue Nov 11, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for ACHN, CLDX, KNDI, ILMN and AMD.
KNDI: 14.26 (+0.53), AMD: 2.62 (+0.01), ACHN: 13.68 (-0.29), CLDX: 17.65 (+3.49), ILMN: 181.75 (+1.25)
Oncothyreon and Celldex Therapeutics Announce Initiation of Combination Immunotherapy Clinical Trial of ONT-10 and Varlilumab
GlobeNewswire - Mon Nov 10, 3:10PM CST
Oncothyreon Inc. (Nasdaq:ONTY) and Celldex Therapeutics, Inc., (Nasdaq:CLDX) today announced that they have initiated a combined clinical trial of ONT-10 and varlilumab. ONT-10 is a therapeutic vaccine targeting the tumor-associated antigen MUC1. Varlilumab is a fully human monoclonal antibody that targets CD27, a critical molecule in the activation pathway of lymphocytes.
CLDX: 17.65 (+3.49), ONTY: 1.70 (unch)
Celldex Presents Varlilumab Proof of Concept Data at SITC Annual Meeting 2014
GlobeNewswire - Fri Nov 07, 9:01AM CST
Celldex Therapeutics, Inc. (Nasdaq:CLDX) today presented a comprehensive review of the Company's Phase 1 single-agent study of varlilumab, focusing on biomarker analyses and confirming significant immunological effects consistent with CD27 costimulation. Varlilumab is an immunotherapy designed to harness the body's natural immune response by enhancing the activation of T cells that can specifically recognize and kill cancer cells. The clinical and immunological activity data presented today add to a growing body of literature supporting the broad study of varlilumab in combination with a number of other anti-cancer agents including but not limited to checkpoint inhibitors, chemotherapies, targeted therapies and vaccines. Varlilumab will enter multiple combination studies in the coming months. The data were presented today in a poster session entitled, "Immune Correlates of Varlilumab (CDX-1127) Treated Cancer Patients are Consistent with CD27 Costimulatory Activity" at the Society for the Immunotherapy of Cancer (SITC) Annual Meeting.
CLDX: 17.65 (+3.49)
Biotech Watchlist Update: Small-Cap Biotechs Struggle, But Investors Remain Enchanted By Big Pharma's Returns
Life Sciences Report - Seeking Alpha - Fri Nov 07, 8:16AM CST
When the biotechnology market hit a speed bump in early 2014, every stock in the sector was jolted. Large-cap biotech and big pharma have largely recovered, but small- and micro-cap companies haven't yet entirely recouped the losses. The performance...
CERS: 4.32 (-0.09), PCYC: 134.89 (+0.46), CLDX: 17.65 (+3.49), INCY: 69.70 (+0.16), BIND: 10.25 (-0.01), CELG: 104.83 (+0.78), OMER: 19.39 (+0.41), VSTM: 9.12 (+0.06), GILD: 101.18 (-0.88), OGXI: 2.20 (+0.02), ANTH: 1.71 (-0.10), NVAX: 5.15 (-0.13)
NWBO: DCVax-Direct Validation And Updated DCVax-L Ph III Modeling
Steven Giardino - at Seeking Alpha - Thu Nov 06, 3:15PM CST
NWBO: 5.59 (-0.20), CLDX: 17.65 (+3.49)
Celldex Falls with Pipeline Update Overshadowing Q3 Results - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 1:57PM CST
Celldex Therapeutics, Inc. (CLDX) amended the protocol for a pivotal study being conducted on glembatumumab vedotin for the treatment of triple negative breast cancer.
BIIB: 306.38 (+0.95), ANIP: 55.95 (+2.00), CLDX: 17.65 (+3.49), AMAG: 34.70 (+0.70)
Celldex (CLDX) in Focus: Stock Tanks 21% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 7:50AM CST
Celldex has been witnessing a flat trend in its current year loss estimates and its share price has been falling for past few days
AGEN: 2.95 (-0.03), CLDX: 17.65 (+3.49), AMAG: 34.70 (+0.70), AFFX: 9.37 (-0.34)
Celldex Therapeutics (CLDX) Stock Drops on Change in Phase 3 Enrollment Criteria
at The Street - Wed Nov 05, 4:00PM CST
Celldex Therapeutics (CLDX) shares are down despite beating analysts' quarterly expectations due to changes in its phase 3 enrollment criteria and wider quarterly losses.
CLDX: 17.65 (+3.49)
Celldex Therapeutics Shares Fall on Breast Cancer Study Changes
at The Street - Wed Nov 05, 3:26PM CST
Investors are selling Celldex today because of concerns the changes made to the METRIC study of CDX-011 introduce more risk
CLDX: 17.65 (+3.49)
CLDX Recent Posts: http://investorshangout.com/Celldex-Therapeut...LDX-53702/
CLDX Celldex Therapeutics Inc Recent Headline News
Celldex Therapeutics (CLDX) Stock Surges Following Brain Tumor Immunotherapy Results
at The Street - 2 mins ago
Shares of Celldex Therapeutics (CLDX) were up in morning trading Monday after the company announced positive results of its immunotherapy in treating a certain type of brain tumor.
CLDX: 17.65 (+3.49)
Celldex Therapeutics: Interim Results For Phase 2 ReACT Trial Are Very Encouraging
Smith On Stocks - at Seeking Alpha - 35 mins ago
CLDX: 17.65 (+3.49)
Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - 1 hr 49 mins ago
CADC: 6.17 (+1.91), INO: 9.98 (-1.02), CLDX: 17.65 (+3.49), HAL: 51.13 (-3.95), ROX: 1.78 (-0.20), SNSS: 1.88 (+0.21), DNR: 9.81 (-1.39), DWA: 22.60 (-3.42), GSAT: 2.79 (-0.18), CMGE: 26.30 (+0.70), FOLD: 6.61 (+0.92), BHI: 67.26 (+7.37)
Celldex up premarket on positive rindopepimut data
Seeking Alpha - at Seeking Alpha - 2 hrs 6 mins ago
CLDX: 17.65 (+3.49)
Biotech Equities Technical Coverage - Orexigen Therapeutics, Novavax, Sunesis Pharma, Celldex Therapeutics, and Navidea Biopharma
PR Newswire - 2 hrs 19 mins ago
Investor-Edge has initiated coverage on the following equities: Orexigen Therapeutics Inc. (NASDAQ: OREX), Novavax Inc. (NASDAQ: NVAX), Sunesis Pharmaceuticals Inc. (NASDAQ: SNSS), Celldex Therapeutics Inc. (NASDAQ: CLDX), and Navidea Biopharmaceuticals Inc. (NYSE MKT: NAVB). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Friday, November 14, 2014, the NASDAQ Composite ended at 4,688.54, up 0.18%, the Dow Jones Industrial Average edged 0.10% lower, to finish the day at 17,634.74, and the S&P 500 closed at 2,039.82, up 0.02%. The gains were broad based as six out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 777.26, down 0.83%, while the index has advanced 9.80% in the last one month. Register for your complimentary reports on these five stocks at:
OREX: 5.57 (-0.08), NAVB: 1.20 (+0.04), NVAX: 5.15 (-0.13), CLDX: 17.65 (+3.49), SNSS: 1.88 (+0.21)
Celldex Therapeutics' (CLDX) CEO Presents Phase 2 ReACT Interim Data at the Society for Neuro-Oncology Annual Meeting (Transcript)
SA Transcripts - at Seeking Alpha - Fri Nov 14, 10:53PM CST
CLDX: 17.65 (+3.49)
After Hour Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Nov 14, 4:38PM CST
HK: 3.04 (-0.06), NTES: 100.29 (-0.35), CIG: 4.87 (+0.05), TSRO: 30.36 (+0.74), DDD: 34.91 (+0.84), CLDX: 17.65 (+3.49), SCMP: 11.83 (+0.53), BVN: 9.23 (+0.02), ABGB: 11.53 (+2.39), SSE: 11.38 (+0.10)
Interim Update from Randomized Phase 2 ReACT Study of Rindopepimut in Recurrent Bevacizumab-naive Glioblastoma Demonstrates Statistically Significant Survival Benefit
GlobeNewswire - Fri Nov 14, 2:35PM CST
-Benefit observed across multiple endpoints in bevacizumab-naïve patients-
CLDX: 17.65 (+3.49)
Celldex Immunotherapy Prolongs Survival for Recurrent Brain Tumor Patients
at The Street - Fri Nov 14, 2:35PM CST
Positive data presented Friday, particularly the statistically significant survival benefit favoring patients treated with rindopepimut, has Celldex planning -- cautiously -- for a conversation with the FDA about accelerated approval.
CLDX: 17.65 (+3.49)
Global Immune Checkpoint Inhibitors Market, 2014-2024: Yervoy, Opdivo and Keytruda to Achieve Blockbuster Status in the Near Future
M2 - Thu Nov 13, 6:55AM CST
Research and Markets (http://www.researchandmarkets.com/research/fkbg4v/immune_checkpoint) has announced the addition of the "Immune Checkpoint Inhibitors Market, 2014 - 2024" report to their offering. The Immune Checkpoint Inhibitors Market, 2014-2024 report provides a comprehensive analysis of the current market landscape and the future outlook of the growing pipeline of Immune Checkpoint Inhibitors. The immuno-oncology market encompasses a myriad of immune checkpoint targeting drugs which can be potentially exploited for the broad range of cancer. CTLA-4 inhibitors were the pioneers in this segment. Yervoy, the flagship molecule from BMS, was the only immunotherapeutic Immune Checkpoint Inhibitor commercially available until other classes recently stepped in. The approval of anti PD-1 drugs and emergence of anti PD-L1 drugs has provided a significant boost to the market. Immune checkpoints are molecules that regulate (stimulate or inactivate) the immune cells. Yervoy (an anti CTLA-4 drug), the foremost drug to be launched in this domain, is currently being mirrored by various other drugs such as Opdivo, Keytruda (both anti PD-1 drugs) and several others under clinical development. The market, with an opportunistic development pipeline, caters to the participation of various market players (big and small) over a common platform. With an ongoing rush to emerge as leaders in the evolving market, various stakeholders have collaborated to establish their foothold in a relatively short time period. Specifically, we expect Yervoy, Opdivo and Keytruda to achieve blockbuster status in the near future. The anticipated success of Immune Checkpoint Inhibitors shall prove to be a harbinger for emerging players and a strong impetus to the development pace of the other pharmaceutical giants. Key Highlights - The market is characterized by the presence of three marketed drugs and 25 drugs in clinical development for oncological indications. This pipeline includes two CTLA-4, eight PD-1 / PD-L1 and 18 novel Immune Checkpoint Inhibitors. The dynamic pipeline also includes several molecules in preclinical / discovery stage; in our research, we identified about 30 such molecules. - BMS, with seven Immune Checkpoint Inhibitors (marketed / clinical development), is the leading player. Other pharmaceutical giants include AstraZeneca, Merck and Roche. Many university spin-offs have emerged in the past two years; their early stage research has been backed by venture funding as well. - Amongst the novel Immune Checkpoint Inhibitors, IDO inhibitors have been the most sought after drug class under development. Though Elotuzumab is the only drug in late stage development, novel checkpoints have paved the way for smaller biotechnology firms to enter the immuno-oncology market. - Collaborations have helped the market reach its current growth trajectory. Specifically, clinical trial collaborations to evaluate Immune Checkpoint Inhibitors as combination therapies are very common; 2014 has already seen 12 such collaborations for a number of molecules. - We expect Immune Checkpoint Inhibitors to be a multi-billion dollar market over the coming decade; during the period 2014 - 2024, our forecast suggests that the market will witness an annualized growth rate of 24.1%. Key Topics Covered: 1. Preface 2. Executive Summary 3. Cancer Therapeutics and Immuno-Oncology 4. Current Market Landscape 5. CTLA-4 Inhibitors: Key Molecules and Future Outlook 6. PD-1 and PD-L1 Inhibitors: Key Molecules and Future Outlook 7. Novel Immune Checkpoint Inhibitors: Key Molecules and Future Outlook 8. Competition in Key Indication Areas 9. Deals and Partnerships 10. Company Profiles 11. Conclusion 12. Appendix 1: Tabulated Data 13. Appendix 2: List of Companies and Organizations Companies Mentioned - Bristol Myer Squibb - AstraZeneca - Merck & Co. - Roche / Genentech - Incyte Corporation - NewLink Genetics - arGEN-X - Seattle Genetics - Pfizer - MacroGenics - Celldex Therapeutics - CureTech - Immutep - Innate Pharma - Sorrento Therapeutics - GlaxoSmithKline - GITR, Inc. For more information visit http://www.researchandmarkets.com/research/fk...checkpoint
MRK: 59.75 (+0.68), INCY: 69.70 (+0.16), CLDX: 17.65 (+3.49), NLNK: 31.48 (+0.94), GSK: 45.87 (+0.13), BMY: 58.19 (+0.24), SRNE: 4.16 (-0.07)
Hematopoietic Stem Cell Transplantation Therapeutic Market Pipeline Overview, Key Players & Drugs Profiles H2 2014
PRWeb - Wed Nov 12, 10:30PM CST
The report "Hematopoietic Stem Cell Transplantation - Pipeline Review, H2 2014" provides comprehensive information on the therapeutic development for Hematopoietic Stem Cell Transplantation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hematopoietic Stem Cell Transplantation and special features on late-stage and discontinued projects. Complete Report is Available @ http://www.rnrmarketresearch.com/hematopoieti...eport.html .
ATNM: 6.00 (+0.08), CLDX: 17.65 (+3.49), ATHX: 1.36 (-0.01), NVS: 94.36 (+0.41)
Critical Alerts For Achillion Pharmaceuticals, Celldex Therapeutics, Kandi Technologies, Illumina and Advanced Micro Devices Released By InvestorsObserver
PR Newswire - Tue Nov 11, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for ACHN, CLDX, KNDI, ILMN and AMD.
KNDI: 14.26 (+0.53), AMD: 2.62 (+0.01), ACHN: 13.68 (-0.29), CLDX: 17.65 (+3.49), ILMN: 181.75 (+1.25)
Oncothyreon and Celldex Therapeutics Announce Initiation of Combination Immunotherapy Clinical Trial of ONT-10 and Varlilumab
GlobeNewswire - Mon Nov 10, 3:10PM CST
Oncothyreon Inc. (Nasdaq:ONTY) and Celldex Therapeutics, Inc., (Nasdaq:CLDX) today announced that they have initiated a combined clinical trial of ONT-10 and varlilumab. ONT-10 is a therapeutic vaccine targeting the tumor-associated antigen MUC1. Varlilumab is a fully human monoclonal antibody that targets CD27, a critical molecule in the activation pathway of lymphocytes.
CLDX: 17.65 (+3.49), ONTY: 1.70 (unch)
Celldex Presents Varlilumab Proof of Concept Data at SITC Annual Meeting 2014
GlobeNewswire - Fri Nov 07, 9:01AM CST
Celldex Therapeutics, Inc. (Nasdaq:CLDX) today presented a comprehensive review of the Company's Phase 1 single-agent study of varlilumab, focusing on biomarker analyses and confirming significant immunological effects consistent with CD27 costimulation. Varlilumab is an immunotherapy designed to harness the body's natural immune response by enhancing the activation of T cells that can specifically recognize and kill cancer cells. The clinical and immunological activity data presented today add to a growing body of literature supporting the broad study of varlilumab in combination with a number of other anti-cancer agents including but not limited to checkpoint inhibitors, chemotherapies, targeted therapies and vaccines. Varlilumab will enter multiple combination studies in the coming months. The data were presented today in a poster session entitled, "Immune Correlates of Varlilumab (CDX-1127) Treated Cancer Patients are Consistent with CD27 Costimulatory Activity" at the Society for the Immunotherapy of Cancer (SITC) Annual Meeting.
CLDX: 17.65 (+3.49)
Biotech Watchlist Update: Small-Cap Biotechs Struggle, But Investors Remain Enchanted By Big Pharma's Returns
Life Sciences Report - Seeking Alpha - Fri Nov 07, 8:16AM CST
When the biotechnology market hit a speed bump in early 2014, every stock in the sector was jolted. Large-cap biotech and big pharma have largely recovered, but small- and micro-cap companies haven't yet entirely recouped the losses. The performance...
CERS: 4.32 (-0.09), PCYC: 134.89 (+0.46), CLDX: 17.65 (+3.49), INCY: 69.70 (+0.16), BIND: 10.25 (-0.01), CELG: 104.83 (+0.78), OMER: 19.39 (+0.41), VSTM: 9.12 (+0.06), GILD: 101.18 (-0.88), OGXI: 2.20 (+0.02), ANTH: 1.71 (-0.10), NVAX: 5.15 (-0.13)
NWBO: DCVax-Direct Validation And Updated DCVax-L Ph III Modeling
Steven Giardino - at Seeking Alpha - Thu Nov 06, 3:15PM CST
NWBO: 5.59 (-0.20), CLDX: 17.65 (+3.49)
Celldex Falls with Pipeline Update Overshadowing Q3 Results - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 1:57PM CST
Celldex Therapeutics, Inc. (CLDX) amended the protocol for a pivotal study being conducted on glembatumumab vedotin for the treatment of triple negative breast cancer.
BIIB: 306.38 (+0.95), ANIP: 55.95 (+2.00), CLDX: 17.65 (+3.49), AMAG: 34.70 (+0.70)
Celldex (CLDX) in Focus: Stock Tanks 21% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 7:50AM CST
Celldex has been witnessing a flat trend in its current year loss estimates and its share price has been falling for past few days
AGEN: 2.95 (-0.03), CLDX: 17.65 (+3.49), AMAG: 34.70 (+0.70), AFFX: 9.37 (-0.34)
Celldex Therapeutics (CLDX) Stock Drops on Change in Phase 3 Enrollment Criteria
at The Street - Wed Nov 05, 4:00PM CST
Celldex Therapeutics (CLDX) shares are down despite beating analysts' quarterly expectations due to changes in its phase 3 enrollment criteria and wider quarterly losses.
CLDX: 17.65 (+3.49)
Celldex Therapeutics Shares Fall on Breast Cancer Study Changes
at The Street - Wed Nov 05, 3:26PM CST
Investors are selling Celldex today because of concerns the changes made to the METRIC study of CDX-011 introduce more risk
CLDX: 17.65 (+3.49)
(0)
(0)Celldex Therapeutics Inc (CLDX) Stock Research Links
Scroll down for more posts ▼